CLINDAMYCIN HYDROCHLORIDE
Clinical safety rating: safe
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
Binds to the 50S ribosomal subunit, inhibiting peptide bond formation and bacterial protein synthesis.
| Metabolism | Hepatic metabolism via CYP3A4, primarily to clindamycin sulfoxide and N-desmethylclindamycin; some metabolites active. |
| Excretion | Approximately 10-20% of clindamycin is excreted unchanged in urine; the remainder is hepatically metabolized and excreted in bile and feces as inactive metabolites. Fecal excretion accounts for about 4% of an administered dose as active drug and 60-70% as metabolites. Renal clearance is minor. |
| Half-life | The terminal elimination half-life of clindamycin is approximately 2-3 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life is prolonged to 8-12 hours. Renal impairment does not significantly alter half-life. |
| Protein binding | Clindamycin is extensively bound to plasma proteins, primarily albumin, with a reported binding of 60-95% (average ~85%). Binding is concentration-dependent and may decrease at high serum concentrations. |
| Volume of Distribution | The apparent volume of distribution (Vd) is 0.6-1.2 L/kg, indicating extensive distribution into tissues and body fluids, including bone, urine, and bile. Vd is not significantly altered in hepatic or renal disease. |
| Bioavailability | Oral bioavailability of clindamycin hydrochloride is approximately 87-90%, but food reduces rate and extent of absorption. The palmitate and phosphate esters are prodrugs with bioavailability similar to the hydrochloride salt. Topical and vaginal formulations have negligible systemic absorption (<5%). |
| Onset of Action | Following oral administration, peak serum concentrations are reached in 45-60 minutes, with clinical onset of activity within 1-2 hours. Intramuscular injection achieves peak levels in 1-3 hours. Intravenous administration produces immediate therapeutic levels. |
| Duration of Action | Duration of action is approximately 6-8 hours for oral and parenteral formulations, supporting every 6-8 hour dosing intervals. For topical or vaginal preparations, local effects may persist longer due to prolonged contact time. |
150-450 mg orally every 6 hours; maximum 1.8 g/day.
| Dosage form | CAPSULE |
| Renal impairment | No adjustment necessary for normal doses. Severe renal impairment (GFR <30 mL/min): consider extended dosing interval (e.g., every 8-12 hours) due to potential accumulation. |
| Liver impairment | Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe hepatic impairment (Child-Pugh C): reduce dose by 50% or extend interval to every 8 hours. |
| Pediatric use | Neonates ≥7 days and infants: 15-20 mg/kg/day orally divided every 6-8 hours. Children: 10-30 mg/kg/day orally divided every 6-8 hours; maximum 1.8 g/day. |
| Geriatric use | Start at lower end of dosing range; monitor for gastrointestinal adverse effects and potential renal impairment; no specific dose adjustment required based on age alone. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
| FDA category | Human |
| Breastfeeding | Clindamycin is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Oral absorption by infant is unlikely to cause adverse effects, but may alter gut flora. Use with caution, especially in preterm or ill infants. |
| Teratogenic Risk | Clindamycin is generally considered low risk in pregnancy. No teratogenic effects have been consistently demonstrated in human studies. FDA category B. Use is acceptable if clearly needed. |
■ FDA Black Box Warning
Clindamycin can cause severe and sometimes fatal colitis, including pseudomembranous colitis, due to Clostridium difficile overgrowth.
| Common Effects | Diarrhea (including C. difficile) |
| Serious Effects |
Hypersensitivity to clindamycin, lincomycin, or any component; history of antibiotic-associated colitis; concomitant use with erythromycin (antagonistic in vitro).
| Precautions | Risk of Clostridium difficile-associated diarrhea; may cause hypersensitivity reactions; caution in renal or hepatic impairment; prolonged use may result in superinfection; neuromuscular blocking effects may be enhanced. |
| Food/Dietary | No significant food interactions; can be taken with or without food. However, taking with food may reduce gastrointestinal upset. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. Monitor for maternal adverse effects (e.g., pseudomembranous colitis) and fetal growth if prolonged therapy. |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. |
| Clinical Pearls | Clindamycin hydrochloride is a lincosamide antibiotic that inhibits bacterial protein synthesis. It is effective against anaerobic bacteria and some gram-positive cocci. Due to risk of pseudomembranous colitis, use with caution in patients with gastrointestinal disease. Monitor liver function in prolonged therapy. Can cause neuromuscular blockade; avoid concurrent use with neuromuscular blocking agents. Dose adjustment not required in renal impairment but caution in hepatic impairment. |
| Patient Advice | Take with a full glass of water to prevent esophageal irritation. · Complete the full course even if symptoms improve. · Report severe or persistent diarrhea, as it may indicate Clostridioides difficile infection. · Avoid alcohol during treatment due to possible disulfiram-like reaction. · Use effective contraception if applicable; may reduce efficacy of oral contraceptives. |